Adermatopathic dermatomyositis

Adermatopathic dermatomyositis, also known as dermatomyositis sine dermatitis or clinically amyopathic dermatomyositis without skin lesions, is a rare subtype of dermatomyositis characterized by the presence of classic dermatomyositis-specific autoantibodies and muscle inflammation (myositis) but without the hallmark skin manifestations typically seen in dermatomyositis. In standard dermatomyositis, patients develop characteristic skin findings such as heliotrope rash, Gottron papules, and photosensitivity alongside proximal muscle weakness. In adermatopathic dermatomyositis, patients present with progressive proximal muscle weakness, elevated muscle enzymes (such as creatine kinase), and inflammatory changes on muscle biopsy or MRI consistent with dermatomyositis, yet they lack clinically apparent dermatologic involvement. This distinction is important because the absence of skin findings can delay diagnosis. The condition primarily affects the musculoskeletal system, leading to symmetric proximal muscle weakness that can impair daily activities such as climbing stairs, rising from a chair, or lifting objects overhead. Patients may also be at risk for interstitial lung disease, dysphagia, and malignancy, similar to other forms of dermatomyositis. Dermatomyositis-specific antibodies, including anti-Mi-2, anti-MDA5, anti-NXP2, or anti-TIF1-gamma, may be detected and can help guide diagnosis and risk stratification. Treatment follows the general approach used for dermatomyositis and typically includes immunosuppressive therapy. First-line treatment usually involves systemic corticosteroids such as prednisone, often combined with steroid-sparing agents including methotrexate, azathioprine, or mycophenolate mofetil. In refractory cases, intravenous immunoglobulin (IVIG), rituximab, or other biologic agents may be considered. Physical therapy and rehabilitation are important adjuncts to maintain muscle strength and function. Regular screening for associated malignancies and pulmonary complications is recommended as part of ongoing management.

Common questions about Adermatopathic dermatomyositis